

**Bijuva (estradiol and progesterone)**  
**Effective 01/01/2023**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Medical and Specialty Medications</b>		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
<b>Exceptions</b>	<b>Non-Specialty Medications</b>		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029

### Overview

Bijuva is a combination product containing estradiol and progesterone FDA approved for the treatment of moderate to severe vasomotor symptoms due to menopause.

### Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with Bijuva, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

### OR

Authorization may be granted for Bijuva if the member meets all following criteria and documentation has been submitted:

1. Member is at least 18 years of age
2. Member has diagnosis of moderate to severe vasomotor symptoms due to menopause
3. Member has had an inadequate response, intolerance or a contraindication to an estrogen and progesterone formulation taken concurrently as separate agents

### Limitations

1. Approvals will be granted for 12 months

### References

1. Bijuva (estradiol and progesterone) [prescribing information]. Boca Raton, FL: Therapeutics MD, Inc; December 2021
2. Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause-2017 update. *Endocr Pract.* 2017;23(7):869-880. doi: 10.4158/EP171828.PS
3. Simon JA, Kaunitz AM, Kroll R, Graham S, Bernick B, Mirkin S. Oral 17 $\beta$ -estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. *Menopause.* 2018. doi: 10.1097/GME.0000000000001271

4. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014; 123:202. Reaffirmed 2018
5. Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017; 1:CD004143

**Review History**

09/18/2019 – Reviewed

09/16/2020 – Reviewed at P&T

09/21/2022 – Reviewed for Sept P&T; Separated Comm/Exch vs MH policies; no clinical updates. Effective 01/01/2023

